THE LONG-RECOGNIZED PHENOMENON of vascular tolerance to organic nitrates remains controversial. Tolerance can be readily demonstrated in man and experimental animals with repeated nitrate dosing, and the predictable attenuation of the hypotensive effects of nitrates is well recognized as a common manifestation of the phenomenon. But the clinical relevance of such observations has been unclear. Until recently, most experts had concluded that tolerance to nitrates was more a theoretical than real problem. Considerable new evidence, however, has documented the presence of clinically important nitrate tolerance in a variety of well-designed studies in cardiac patients given long-acting nitrates for 1 week or more."2 In addition, recent reports indicate that tolerance can be demonstrated as early as 18 to 24 hr after administration of sustained concentrations of nitroglycerin (NTG) or isosorbide dinitrate (ISDN). This Perspective reviews the evidence from recent investigations supporting the concept that tolerance to organic nitrates is a genuine problem. Studies using transdermal, intravenous, and buccal NTG raise new questions about the mechanisms and clinical importance of tolerance. It is proposed that the type of nitrate compound has major relevance as to whether tolerance will develop with long-term dosing. Furthermore, a hypothesis is presented that nitrate tolerance can be avoided or minimized with dosing strategies that use intermittent administration of nitrates with nonsustained action, using the smallest effective dose, and providing a daily nitrate-free interval.
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Nitrate delivery systems: relationship to nitrate tolerance. Although it is generally believed that all organic nitrates have similar hemodynamic actions, recent evi-dence indicates that available nitrate formulations, each with a different pharmacokinetic profile, have varying propensities to induce tolerance. Short-acting formulations. Sublingual NTG and ISDN remain the first-line drugs for acute angina attacks. Their rapid onset of action and short duration of effect appear to prevent the development of tolerance. An immediate-acting oral NTG spray, with an onset of effect as rapid as that of sublingual NTG, is now available in the United States. None of these drugs have been implicated in the development of tolerance.
Oralformulations. Oral nitrates, once considered to be of questionable value, have taken on new legitimacy in the past 10 years. Contrary to previous beliefs, hepatic nitrate biodegradation is not so complete as to preclude therapeutic plasma levels of NTG or ISDN after oral dosing.1 Fung3 has recently shown that organic nitrates are metabolized by vascular smooth muscle as well as by the liver, suggesting that vascular uptake rather than hepatic degradation may account for the majority of nitrate metabolism after oral dosing. Veins have a greater avidity for nitrate uptake than arteries, perhaps explaining the potent venodilating effects of nitrates at extremely low doses.
Many clinical studies have documented the appearance of tolerance after long-term dosing with oral nitrates. In several studies of patients with angina pectoris and congestive heart failure, long-term use of oral nitrates has resulted in attenuation of one or more variables of nitrate action, 2.4 even when clinical efficacy remained intact.1 4 Tolerance to the hypotensive actions of oral nitrates has been repeatedly documented in the presence of persistent antianginal activity.'
Ointment. NTG ointment remains a popular formulation, especially for hospitalized patients. Relatively few data are available on tolerance with long-term use of NTG ointment, but tolerance has been documented with repeated application of this preparation.
Intravenous formulations. Intravenous NTG is widely used in acutely ill patients. Its rapid onset and disap-pearance of action have suggested that tolerance does not occur with this formulation. However, two recent studies have shown that sustained infusions of intravenous NTG can result in vascular tolerance within 24 hr. , 6 Buccal NTG. Buccal NTG (BNTG)-NTG impregnated in a methylcellulose polymer in tablet form-is positioned in the buccal pouch between the upper teeth and inner lip. A gellike seal quickly forms once the tablet becomes hydrated. BNTG remains in a stable position in the mouth for up to 6 hr, continuously releasing NTG into the circulation.
The unique feature of the buccal or transmucosal formulation is its extremely rapid onset of action, comparable to that of sublingual NTG, coupled with sustained effects that persist as long as the pill remains intact in the mouth. The duration of action is variable, averaging 4 to 5 hr. BNTG rapidly produces therapeutic plasma NTG levels and is a very effective antianginal agent when compared with placebo in short-term dosing trials.
Several protocols investigating nitrate tolerance have compared BNTG with other nitrate formulations. Available data indicate that it is very difficult to induce NTG tolerance with this compound. Parker et at.7 compared BNTG (3 mg tid) with oral ISDN (30 mg qid) in a double-blind, serial exercise test protocol in patients with angina. After initial dosing, both compounds resulted in antianginal protection for up to 5 hr. However, after 2 weeks of continuous therapy there was a significant decrease in the duration of antianginal protection provided by ISDN but not with BNTG, documenting that tolerance had occurred with ISDN. The difference in dose scheduling (tid vs qid) in this protocol poses interpretational problems; the additional (fourth) daily dose of ISDN regimen presumably provided a longer duration of nitrate exposure to vascular tissue than the BNTG regimen. In a study from West Germany investigating four different nitrate formulations in patients with angina, BNTG was the only compound that did not produce attenuation of the pulmonary artery pressure response to exercise after longterm dosing.8 Other formulations in the protocol included oral NTG, sustained-action ISDN, and isosorbide-5-mononitrate. Another short-term dosing protocol compared BNTG with transdermal NTG and demonstrated tolerance with the topical patch but not with the buccal formulation. 9 The pharmacokinetics of BNTG are characterized by a brisk rise followed by a rapid decline in systemic plasma NTG levels, with a usual duration of action of 3 to 5 hr. If the last dose of BNTG is taken in the late afternoon or early evening, an NTG-free interval of at least 8 to 12 hr is ensured. This drug profile appears to be important in protecting patients from nitrate tolerance and represents an ideal pharmokinetic model for optimal nitrate therapy Transdermal NTG. The transdermal NTG (TDNTG) systems consist of NTG impregnated in a polymer or silicone reservoir, allowing steady-state absorption of NTG across the skin for 24 hr or more. Plasma concentrations remain constant for at least 24 hr. The concept of once-daily application of a patch or disc has met with considerable commercial success, but data documenting clinical effectiveness have conflicted.Ì mportant and unresolved issues regarding nitrate tolerance have been raised by a number of investigations using TDNTG. The unusual pharmacokinetic profile of this formulation appears to be intimately related to tolerance. Questions of TDNTG efficacy were initially raised when several well-controlled short-term studies using the formulation in conventional or low dosage (5 to 10 mg NTG/24 hr) could not demonstrate an antianginal effect at any testing interval. This is consistent with the low plasma NTG concentrations obtained after small doses of TDNTG. When larger amounts of TDNTG are given, antianginal efficacy is consistently demonstrable in doubleblind clinical trials. Exercise improvement for up to 8 hr after administration has been documented with TDNTG doses ranging from 15 to 45 mg NTG/24 hr.1 TDNTG has been shown to lower left ventricular filling pressure and right heart pressure in patients with congestive heart failure. Most investigations have required TDNTG dosages of 15 to 120 mg/24 hr to produce beneficial hemodynamic changes., which are relatively unpredictable at doses under 60 mg/24 hr. 12
The major concern raised by studies using TDNTG is the phenomenon of acute tachyphylaxis or tolerance to NTG that consistently appears within 12 to 24 hr after initial dosing. In many well-controlled studies of TDNTG in patients with angina pectoris or congestive heart failure, attenuation or disappearance of some or all nitrate actions has been documented to occur within 24 hr, even when very large amounts (up to 120 mg/24 hr) were administered. This phenomenon is not caused by decreased NTG availability or by a decline in plasma NTG concentrations. It is of interest that other recent studies of patients with angina pectoris using nitrates with a similarly protracted duration of action have shown an identical attenuation of effect by 24 hr. For example, a long-acting ISDN cream'3 and sustained-release oral isosorbide-5-mononitrate,'4 preparations that provide 24 hr continuous nitrate delivery, have been shown to lose their antianginal action within 24 hr after initial dosing in spite of sustained therapeutic nitrate plasma levels and clear-cut antianginal efficacy for 2 to 8 hr after administration.
These data strongly suggest that vascular responsiveness to nitrates rapidly becomes attenuated with formulations providing a pharmacokinetic profile of continuous nitrate release over 24 hr or more. In patients with angina, Reichek at al.9 compared continuous administration of BNTG vs TDNTG using repetitive exercise testing over 24 hr and documented that BNTG maintained antianginal effectiveness at 10 and 24 hr whereas TDNTG had lost its protective effect at the same intervals. These results suggest that even with around-the-clock nitrate therapy, the rate of input of NTG into the circulation is an important factor affecting tolerance.
Chronic Nitrate tolerance appears to be related to sulfhydryl (SH) availability within vascular tissue. It is currently believed that NTG and organic nitrates produce relaxation of vascular tissue through a complex cascade of intracellular events. Within the vascular smooth muscle cell, organic nitrates are initially converted to nitric acid and subsequently to S-nitrosothiols, SH-containing compounds with a short half-life. Nitrosothiols activate guanylate cyclase, which in turn stimulates production of cyclic GMP. 5 An increase in intracellular cyclic GMP is the final common step leading to vasodilatation after administration of nitrates and sodium nitroprusside.
The availability of sufficient SH groups in the form of intracellular thiols appears to be necessary for the conversion of organic nitrates to S-nitrosothiols. It has been postulated that vascular tolerance to nitrates is associated with decreased intracellular stores of reduced SH groups; thus, vasodilatation cannot occur as readily as in the nontolerant state.3 15 The cyclic GMP response to nitrates is diminished in the presence of tolerance.'5 Removal of organic nitrates from contact with the blood vessel wall for a period of time restores vascular responsiveness, possibly by enhancing SH availability. Thus a nitrate-free interval appears to be essential to allow intracellular metabolism sufficient time to provide an adequate supply of SH groups.
Administration of exogenous thiols in the form ofNacetylcysteine enhances nitrate vascular effects in the nontolerant state. 16 Such an approach could be a potential therapeutic strategy to restore vascular responsiveness in the tolerant state. A recent preliminary report suggested that oral N-acetylcysteine is able to reverse nitrate tolerance induced by continuous use of intravenous NTG in patients with congestive heart failure.6
Relationship oftolerance to dosingformulation andfrequency of administration. Clinical experience with sustainedaction nitrates as well as the results of studies comparing various nitrate dosing regimens and formulations support the concept that duration of action, size of dose, and frequency of administration of the parent nitrate compound are important factors determnining whether tolerance will develop. In a number of comparative clinical studies of angina pectoris using two or more nitrate dosing regimens, the shorter duration of action, smaller dose, or less frequent dosing schedule prevented the appearance of partial or complete nitrate tolerance. 7 Importance ofa nitrate-free interval. Removal of vascular smooth muscle from exposure to nitrate rapidly restores blood vessel responsiveness to nitrates, even after complete tolerance is demonstrable. The minimal duration of a nitrate-free interval required is uncertain and probably varies with the type of formulation and the size and frequency of the dose. Parker's group has shown that in ISDN-tolerant subjects, blood pressure and heart rate responses to ISDN are restored within 21 hr after the last dose. 18 Other data are conflicting as to the requisite length of the nitrate-free period. It is conceivable that the nitrate-free interval necessary to pre-vent tolerance may be shorter than required to reverse established vascular tolerance.
In the study comparing oral ISDN qid with BNTG tid, tolerance to ISDN developed after 2 weeks but was not found with BNTG.7 This indicates that nitrate tolerance is preventable by using a less frequent dosing interval, a shorter-acting nitrate, or both. Reichek's study comparing BNTG with TDNTG is also consistent with this hypothesis; BNTG dosing every 4 to 5 hr in awake subjects produced sustained antianginal action at 1, 4, 6, 10, and 24 hr, whereas TDNTG resulted in beneficial action at 1, 4, and 6 hr but attenuation of effect at 10 and 24 hr.9 Moreover, data from West Germany are consistent with the hypothesis that a nitrate-free interval is essential to avoid tolerance. One study compared a high-dose, sustained-release formulation of ISDN every 12 hr with once-daily dosing.2
The twice-daily schedule induced tolerance whereas the single-dose regimen did not, and the absence of tolerance correlated with lower plasma levels of 5-ISMN, the major active metabolite of ISDN. The same investigators have subsequently shown that twicedaily dosing at 8 A.M. and 2 P.M. with sustained-release ISDN for 2 weeks maintains antianginal activity, whereas twice-daily dosing every 12 hr produces tolerance.
Conclusions. It is clear that the problem of nitrate tolerance is more common than previously thought. However, it is not surprising that most patients who use nitrates regularly do not appear to develop obvious clinical nitrate tolerance. Antianginal drug effects are notoriously difficult to separate from placebo and many individuals do not take their medications consistently three to four times daily. Nevertheless, a number of protocols have demonstrated that the antianginal actions of nitrates as well as nitrate-induced venodilatation in patients with congestive heart failure and in normal subjects become partially or completely attenuated with long-term dosing. Not all studies are in agreement.
There is substantial evidence to support the hypothesis that sustained nitrate plasma and tissue concentrations present continuously over 18 to 24 hr readily induce vascular hyporesponsiveness to nitrates. Such a pharmacokinetic profile can be achieved with protracted action formulations (TDNTG, long-acting ISDN or NTG ointment, sustained-release ISDN or 5-ISMN), continuous infusion of intravenous NTG, frequent nitrate dosing regiments, or large doses of organic nitrates. On a cellular level, tolerance appears correlated with a relative depletion of thiol groups within smooth muscle cells and is associated with partial inhibition of vascular nitrate metabolism, elevated plasma nitrate levels, and decreased systemic nitrate clearance.
A nitrate-free interval reverses or prevents tolerance and restores vascular responsiveness. It is not certain how long this interval should be, but it is probably a minimum of 10 to 12 hr, varying with the nitrate for mulation and dose.
Recommendations. To avoid nitrate tolerance, one should administer as small a dose as possible. On the other hand, many patients are undertreated with organic nitrates; the clinical experience with oral nitrates in the 1960s and 1970s as well as the disappointing results with low-dose TDNTG indicate the importance of giving a therapeutically sufficient dose of active drug. Sustained-action nitrate compounds should probably be avoided. Less frequent dosing schedules, such as two or three times daily, should be used whenever possible. Limited experience with long-term use of TDNTG and sustained-action ISDN cream indicates that clinically important tolerance is quickly induced by these formulations. It has been suggested that TDNTG patches should be removed each day after 10 to 12 hr to avoid the induction of tolerance,12 which is consistent with our current understanding of nitrate tolerance and seems appropriate in light of recent data.
The new nitrate delivery systems have raised some unexpected and disturbing questions about nitrate tolerance. Considerably more information is needed to unravel the complexities of this issue. Clinicians can prevent nitrate tolerance by exercising caution and thoughtful planning in the prescription of dosing regimens for patients with angina pectoris or congestive heart failure.
